Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Abbvie (ABBV) PT Raised to $200 at Goldman Sachs
July 26, 2024 5:53 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $200.00 (from $190.00) while maintaining a Buy rating.
The analyst comments "Even amidst expectations that Immunology would once again deliver, we see basis for the factors underpinning growth for both Skyrizi and Rinvoq to continue propelling upside - including NBRx dynamics that... More
William Blair Reiterates Outperform Rating on Abbvie (ABBV)
July 26, 2024 5:37 AM EDTWilliam Blair analyst Tim Lugo reiterated an Outperform rating on Abbvie (NYSE: ABBV).
The analyst comments "Stock thoughts: We believe AbbVie has a strong and durable growth profile over the coming years thanks to its strong growth platform, recently augmented by the... More
Abbvie (ABBV) PT Raised to $210 at Truist Securities
July 25, 2024 4:12 PM EDTTruist Securities analyst Robyn Karnauskas raised the price target on Abbvie (NYSE: ABBV) to $210.00 (from $195.00) while maintaining a Buy rating.
The analyst comments "ABBV reported strong 2Q24 results with top and bottom line beats, led by Skyrizi/RInvoq. Given the share... More
Abbvie (ABBV) PT Raised to $210 at JPMorgan
July 25, 2024 3:56 PM EDTJPMorgan analyst Chris Schott raised the price target on Abbvie (NYSE: ABBV) to $210.00 (from $190.00) while maintaining a Overweight rating.
The analyst comments "Exiting 2Q results, we our updating our model and wanted to share our key changes. Overall, we are increasing our estimates to... More
